Connection
John Imig to Cardiovascular Diseases
This is a "connection" page, showing publications John Imig has written about Cardiovascular Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.669 |
|
|
|
-
Imig JD. Bioactive lipids in hypertension. Adv Pharmacol. 2023; 97:1-35.
Score: 0.598
-
Imig JD. SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection. Clin Sci (Lond). 2022 03 31; 136(6):431-434.
Score: 0.554
-
Imig JD, Jankiewicz WK, Khan AH. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture. Hypertension. 2020 07; 76(1):3-15.
Score: 0.488
-
Imig JD. Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. Pharmacol Ther. 2018 12; 192:1-19.
Score: 0.427
-
Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009 Oct; 8(10):794-805.
Score: 0.233
-
Imig JD. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev. 2006; 24(2):169-88.
Score: 0.180
-
Imig JD. Eicosanoid blood vessel regulation in physiological and pathological states. Clin Sci (Lond). 2020 10 30; 134(20):2707-2727.
Score: 0.125
-
Imig JD. ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses: EDHF Involvement. Hypertension. 2004 Mar; 43(3):533-5.
Score: 0.039
-
Campbell WB, Imig JD, Schmitz JM, Falck JR. Orally Active Epoxyeicosatrienoic Acid Analogs. J Cardiovasc Pharmacol. 2017 Oct; 70(4):211-224.
Score: 0.025